Eisai Presents New Findings on Lecanemab’s Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022
TOKYO and CAMBRIDGE, Mass., Aug 4, 2022 – (JCN Newswire via SEAPRWire.com) – E…
Read Moreป้ายกำกับ: dose
Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
TOKYO, Sep 27, 2021 – (JCN Newswire via SEAPRWire.com) – AbbVie GK, Eisai Co.,…
Read More